These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 38996147

  • 1. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases.
    Ono M, Kobayashi S, Masakazu H, Ishida M, Sato H, Okutomo K, Shirai Y, Takahashi K, Yamada M, Fujino N, Yamanda S, Yanai M.
    Medicine (Baltimore); 2024 Jul 12; 103(28):e38920. PubMed ID: 38996147
    [Abstract] [Full Text] [Related]

  • 2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN.
    Drugs; 2021 Apr 12; 81(5):575-586. PubMed ID: 33765296
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S.
    Mod Rheumatol; 2021 Jan 12; 31(1):13-19. PubMed ID: 32964766
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
    Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M.
    Eur Respir J; 2019 Sep 12; 54(3):. PubMed ID: 31285305
    [Abstract] [Full Text] [Related]

  • 9. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, Tomassetti S, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M, INBUILD Trial Investigators.
    Respir Res; 2021 Mar 16; 22(1):84. PubMed ID: 33726766
    [Abstract] [Full Text] [Related]

  • 10. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE, Kahn N, Wälscher J, Sarmand N, Polke M, Lars K, Eichinger M, Heussel CP, Palmucci S, Sambataro FM, Sambataro G, Sambataro D, Vancheri C, Kreuter M.
    BMC Pulm Med; 2019 Nov 12; 19(1):213. PubMed ID: 31718637
    [Abstract] [Full Text] [Related]

  • 11. Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.
    Mira-Avendano I, Kaye M.
    Ther Adv Respir Dis; 2024 Nov 12; 18():17534666241266343. PubMed ID: 39113425
    [Abstract] [Full Text] [Related]

  • 12. Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study.
    Komatsu M, Yamamoto H, Ichiyama T, Kawakami S, Uehara T, Yoshikawa Y, Kitaguchi Y, Ushiki A, Yasuo M, Hanaoka M.
    PLoS One; 2022 Nov 12; 17(2):e0262795. PubMed ID: 35113907
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
    Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK, INBUILD Trial Investigators.
    N Engl J Med; 2019 Oct 31; 381(18):1718-1727. PubMed ID: 31566307
    [Abstract] [Full Text] [Related]

  • 15. Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease.
    Yamakawa H, Sato S, Ohta H, Kusano K, Kawabe R, Oba T, Uzuka C, Sasaki H, Akasaka K, Amano M, Takemura T, Araya J, Matsushima H.
    Respir Investig; 2024 Jul 31; 62(4):551-557. PubMed ID: 38663299
    [Abstract] [Full Text] [Related]

  • 16. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
    Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, Dellaripa PF, Aringer M, Pope J, Distler O, James A, Schlenker-Herceg R, Stowasser S, Quaresma M, Flaherty KR, INBUILD Trial Investigators.
    Arthritis Rheumatol; 2022 Jun 31; 74(6):1039-1047. PubMed ID: 35199968
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
    Inoue Y, Wells AU, Song JW, Xu Z, Kitamura H, Suda T, Okamoto M, Müller H, Coeck C, Rohr KB, Kolb M, Brown KK.
    Respirology; 2023 May 31; 28(5):465-474. PubMed ID: 36642509
    [Abstract] [Full Text] [Related]

  • 19. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F, Sgalla G, Iovene B, Bruni T, Richeldi L.
    Expert Opin Pharmacother; 2018 Feb 31; 19(2):167-175. PubMed ID: 29327616
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
    Rodríguez-Portal JA.
    Drugs R D; 2018 Mar 31; 18(1):19-25. PubMed ID: 29209910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.